Larimar Therapeutics develops treatments for rare diseases, starting with a drug candidate for Friedreich's ataxia that uses its cell penetrating peptide platform. It last closed at $3.14 on Nov 20, down 2.48% on the day. The next earnings report for LRMR is expected around Mon, Jan 11, 2027, after the close. Over its last 8 reports the stock moved an average of 6.0% the session after earnings. Over the last 12 months LRMR insiders bought $26.1M of stock on the open market and sold $0, according to SEC Form 4 filings.
AI Auto Pilots
Is LRMR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LRMR.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on LRMRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
LRMR · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend
The stock is 14% above its 20 day and 9% above its 50 day average. It is 20% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 61). The nearest support is the Pivot at $3.11, and the nearest resistance the Pivot R1 at $3.25.
Short trendBullish
Long trendBearish
MomentumStrong
StretchNormal
VolatilityHigh, 8.8%/day
Key levels
$6.4252 week high+104.5%
$3.76200 day average+19.7%
$3.67Swing high (May 27)+16.9%
$3.40100 day average+8.3%
$3.25Pivot R1+3.5%
$3.14Last close
$3.11Pivot−1.0%
$3.04Swing low (Jun 8)−3.2%
$2.99Pivot S1−4.8%
$2.8550 day average−9.2%
$2.7020 day average−14.0%
$1.9252 week low−38.9%
Indicators
RSI (14)
60.59
Strong, overbought above 70
Neutral
MACD
0.12
Above its signal line
Bullish
Stochastic
78.0
Middle of its range
Neutral
ADX (14)
25.4
Trending up
Williams %R
-30.4
Oversold below −80, overbought above −20
Neutral
CCI (20)
110.5
Oversold below −100, overbought above 100
Overbought
Rate of change
+31.4%
Change over 10 sessions
Bullish
ATR (14)
$0.28
Typical daily range, 8.8% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Below
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumFading
StretchNormal
VolatilityNormal, 18.6%/day
Key levels
$6.4252 week high+104.5%
$3.76200 day average+19.7%
$3.67Swing high (May 27)+16.9%
$3.40100 day average+8.3%
$3.25Pivot R1+3.5%
$3.14Last close
$3.11Pivot−1.0%
$3.04Swing low (Jun 8)−3.2%
$2.99Pivot S1−4.8%
$2.8550 day average−9.2%
$2.7020 day average−14.0%
$1.9252 week low−38.9%
Indicators
RSI (14)
47.71
Middle of its range
Neutral
MACD
-0.32
Below its signal line
Bearish
Stochastic
37.0
Middle of its range
Neutral
ADX (14)
17.6
No clear trend
Williams %R
-51.1
Oversold below −80, overbought above −20
Neutral
CCI (20)
-25.7
Oversold below −100, overbought above 100
Neutral
Rate of change
−19.9%
Change over 10 sessions
Bearish
ATR (14)
$0.58
Typical daily range, 18.6% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LRMR
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how LRMR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow LRMR usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for LRMRHow many large options trades hit LRMR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in LRMR in the last 90 days.
From SEC Form 4 filings by LRMR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LRMR is in one of them and how their past LRMR trades turned out.
Larimar Therapeutics is a biotechnology company based in Bala Cynwyd, Pennsylvania, that develops treatments for complex rare diseases. Its lead candidate, nomlabofusp, is a drug given by injection under the skin that is designed to deliver frataxin, a protein the body needs, to patients with Friedreich's ataxia. The company uses its cell penetrating peptide platform, which helps therapeutic molecules cross cell membranes, and it aims to apply that platform to other rare diseases. The drug is still in clinical development and is not yet approved for sale.